Evoke Pharma appoints new CFO, shareholders approve share increase and reverse split authority

Evoke Pharma Inc

Mark A. Kowieski appointed CFO effective May 22, 2024; annual base salary $390,000, target bonus 40%.
CEO Matthew D'Onofrio base salary raised to $615,000, target bonus to 60%.
Shareholders approved increase in authorized common shares from 50M to 100M.
Shareholders approved amendment to 2013 Equity Incentive Award Plan, adding 4M shares plus evergreen provision (up to 6% of outstanding annually).
Shareholders granted Board authority to effect reverse stock split within 1 year, range 1:2 to 1:20.

item 5.02 item 5.03 item 5.07 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Mark A. Kowieski

Chief Financial Officer

Evoke Pharma Inc

Effective: 2024-05-22
Filed: May 28, 2024, 7:59 PM ET

On May 22, 2024, the Board appointed Mr. Kowieski, age 47, as Chief Financial Officer ("CFO") of Evoke Pharma, Inc. (the "Company") effective May 22, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Mark A. Kowieski was appointed as Chief Financial Officer at Evoke Pharma Inc.

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On May 22, 2024, the Board appointed Mr. Kowieski, age 47, as Chief Financial Officer ("CFO") of Evoke Pharma, Inc. (the "Company") effective May 22, 2024.

View on SEC.gov

Source: SEC EDGAR

accession 0000950170-24-065229

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.